Q-omics provides the consensus-scored MAOA profile across patient tissues and cancer cell-line models. MAOA expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAOA is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, MAOA protein abundance shows 20,388 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where MAOA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAOA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAOA survival associations across molecular data types. MAOA RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAOA RNA expression–survival associations across cancer types. High MAOA expression shows unfavorable associations in STAD, but favorable associations in KIRC, UVM, DLBC, BRCA and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAOA RNA expression.
This table summarizes MAOA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAOA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAOA shows lower tumor expression in COAD, KICH, KIRP, UCEC, LUAD and LUSC. The COAD box plot shows higher MAOA RNA expression in normal versus tumor tissue (log2 FC = −2.317, t-test p < 0.001).
This table shows molecular features associated with MAOA in patient tissues and cancer cell lines. In patient samples, MAOA shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAOA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
